Lilly Supports Direct Relief’s Efforts To Expand Access to Medicines by Improving Cold Chain Capacity - Seite 2

"We are grateful to Lilly for their support of this crucial initiative. Their dedication to global health and access to essential medical products is making a real difference in the lives of those in need," said Direct Relief President and CEO Thomas Tighe. "The lack of cold chain distribution capacity in much of the world already prevents many people from accessing the medications and therapies they need, even when they are free. If this issue is not addressed, the divide between those who have access to essential medical products and those who don't will only widen."

In its 2022 fiscal year, Direct Relief delivered more than 47 million defined daily doses, the average dose per day, of temperature-controlled medications valued at $656 million (wholesale acquisition cost), a 600% increase from five years earlier in 2018. The organization operates 8,300 square feet of refrigerated warehouse space capable of storing up to 677 pallets of temperature-sensitive medicine.

By ensuring that resource-constrained regions of the world have medical refrigeration capacity at the last mile of delivery, more people will have access to the medications they need to live healthy lives.

About Lilly

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram and LinkedIn.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 771,72$, was eine Steigerung von +5,00% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

HSBC Trinkaus & Burkhardt GmbH

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer